Ok-To The Moon - Tiger Brokers Online Investing Community

2
Comment
Favorite

qiqi2
2022-06-08

Novavax Surges 23% After FDA Panel Votes In Favor Of Its Covid Shot

In a nearly unanimous move, a panel of Food and Drug Administration experts voted in favor of recomm

Novavax Surges 23% After FDA Panel Votes In Favor Of Its Covid Shot

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9051349213,"tweetId":"9051349213","gmtCreate":1654647757832,"gmtModify":1676535484153,"author":{"id":3573803041677956,"authorId":3573803041677956,"authorIdStr":"3573803041677956","name":"qiqi2","avatar":"https://static.tigerbbs.com/836c56071da9ab9941909ee1186113fe","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9051349213","repostId":1198963241,"repostType":4,"repost":{"id":"1198963241","pubTimestamp":1654645107,"share":"https://www.laohu8.com/m/news/1198963241?lang=&edition=full","pubTime":"2022-06-08 07:38","market":"us","language":"en","title":"Novavax Surges 23% After FDA Panel Votes In Favor Of Its Covid Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1198963241","media":"investor's business daily","summary":"In a nearly unanimous move, a panel of Food and Drug Administration experts voted in favor of recomm","content":"<html><head></head><body><p>In a nearly unanimous move, a panel of Food and Drug Administration experts voted in favor of recommending <b>Novavax</b>&#39;s (NVAX) Covid vaccine for emergency authorization. NVAX stock rocketed after the vote. </p><p>All but one member of the FDA&#39;s Vaccines and Related Biological Products Advisory Committee voted in favor of Novavax&#39;s two-dose vaccine. One panelist abstained.</p><p>&#34;The data we&#39;ve seen today have been impressive and support the original vision for this vaccine from its beginning,&#34; panelist Dr. Bruce Gellin said, explaining his yes vote. He noted the lower level of protein used in Novavax&#39;s shot appears to lead to lower side effects. &#34;But we don&#39;t know whether that attribute continues to be relevant today.&#34;</p><p>That puts Novavax in good company. Novavax tested its Covid shot against the dominant strain two years ago, just like <b>Pfizer</b>(PFE) and <b>Moderna</b>(MRNA). But the effectiveness of all three vaccines has waned as the virus mutates and creates new variants.</p><p>The benefit of Novavax&#39;s shot, however, is that it uses a protein-based technology, which could sway people hesitant to receive shots comprised of newer messenger RNA technology. Panelist Dr. Michael Nelson said the vaccine will likely require a third dose.</p><p>&#34;I do feel that it does offer something for fulfilling that unmet need, including those populations who have hesitancy with regards to the messenger RNA vaccines,&#34; he said after the vote. There are other advantages in terms of storage and supply chain challenges.</p><p>In after-hours action, NVAX stock soared 22.86% to 58.41. Shares were halted during the regular session ahead of the vote.</p><p><img src=\"https://static.tigerbbs.com/9d7eeb6334f9136496d2185015055875\" tg-width=\"822\" tg-height=\"837\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><h2>NVAX Stock: FDA Decision Next</h2><p>The meeting is an important step ahead of potential authorization of the two-dose vaccine. Out of 22 panelists, 21 said the benefits of the Novavax shot outweigh its risks for adults. The FDA often follows the committee&#39;s recommendation.</p><p>After that, the vaccine heads to the Centers for Disease Control and Prevention.</p><p>Dr. Peter Marks, of the FDA, acknowledged the benefit of offering another vaccine option to help prevent severe cases of Covid. But it will be up to the CDC to determine where it lies in the lineup of preferred vaccines.</p><p>Panelist Dr. Mark Sawyer notes the audience for the Novavax vaccine is largely &#34;vaccine-hesitant people,&#34; many of whom have likely already experienced natural Covid infections.</p><p>In one of its key studies, 7% of participants had prior Covid infections before receiving Novavax&#39;s shot. Their responses were not calculated in the effectiveness analysis. However, in general, they experienced a boost in antibodies, Novavax Chief Medical Officer Filip Dubovsky said. They also didn&#39;t have any additional side effects compared to previously uninfected participants.</p><h2>Data Updates Desired</h2><p>Novavax tested its Covid shot against an ancestral strain of the Covid-causing virus — just like its predecessors Pfizer, Moderna and<b>Johnson &amp; Johnson</b>(JNJ). And it&#39;s beginning to look like vaccine-induced immunity lasts six months or less with new variants on the loose.</p><p>&#34;It is disappointing that we don&#39;t have more updated information because we&#39;re looking at the (effectiveness) against strains that don&#39;t exist any longer,&#34; panelist Dr. Eric Rubin said. But &#34;if there&#39;s a population of patients who are going to take this and not existing vaccines, then I think it&#39;s pretty compelling.&#34;</p><p>Still,NVAX stockremains under pressure. As of Monday&#39;s close, shares were below their50-dayand200-daymoving averages, according toMarketSmith.com. The stock also experienced a dive last week when the FDA posted briefing documents ahead of the advisory committee meeting.</p><p>The documents suggested Novavax&#39;s shot could cause heart inflammation known as myocarditis and pericarditis.  The FDA noted there were six cases in recipients of the vaccine. In comparison, there was just one case in a placebo recipient.</p><h2>Young Males Are More Susceptible</h2><p>Of the six cases, four occurred in males under the age of 30. The FDA said it couldn&#39;t rule out a causal relationship between Novavax&#39;s vaccine and the cases of myocarditis, causing NVAX stock to dive. But Novavax argued this demographic is at a heightened risk of myocarditis due to viral infection. In fact, myocarditis is a risk of Pfizer&#39;s and Moderna&#39;s vaccines in young men and boys.</p><p>&#34;We have learned that we can expect to see natural background events of myocarditis in any sufficiently large database, and that young males are at higher risk,&#34; Novavax said in a written statement. &#34;Myocarditis is most often caused by nonspecific viral infections.&#34;</p><p>The company said there&#39;s &#34;insufficient evidence to establish a causal relationship&#34; between its shot and episodes of myocarditis/pericarditis. Still,NVAX stock tumbled20% on Friday.</p></body></html>","source":"lsy1610612141385","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Surges 23% After FDA Panel Votes In Favor Of Its Covid Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Surges 23% After FDA Panel Votes In Favor Of Its Covid Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-08 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/nvax-stock-halted-as-fda-mulls-its-rival-to-covid-shots-from-pfizer-moderna/><strong>investor's business daily</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a nearly unanimous move, a panel of Food and Drug Administration experts voted in favor of recommending Novavax's (NVAX) Covid vaccine for emergency authorization. NVAX stock rocketed after the ...</p>\n\n<a href=\"https://www.investors.com/news/technology/nvax-stock-halted-as-fda-mulls-its-rival-to-covid-shots-from-pfizer-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.investors.com/news/technology/nvax-stock-halted-as-fda-mulls-its-rival-to-covid-shots-from-pfizer-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198963241","content_text":"In a nearly unanimous move, a panel of Food and Drug Administration experts voted in favor of recommending Novavax's (NVAX) Covid vaccine for emergency authorization. NVAX stock rocketed after the vote. All but one member of the FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of Novavax's two-dose vaccine. One panelist abstained.\"The data we've seen today have been impressive and support the original vision for this vaccine from its beginning,\" panelist Dr. Bruce Gellin said, explaining his yes vote. He noted the lower level of protein used in Novavax's shot appears to lead to lower side effects. \"But we don't know whether that attribute continues to be relevant today.\"That puts Novavax in good company. Novavax tested its Covid shot against the dominant strain two years ago, just like Pfizer(PFE) and Moderna(MRNA). But the effectiveness of all three vaccines has waned as the virus mutates and creates new variants.The benefit of Novavax's shot, however, is that it uses a protein-based technology, which could sway people hesitant to receive shots comprised of newer messenger RNA technology. Panelist Dr. Michael Nelson said the vaccine will likely require a third dose.\"I do feel that it does offer something for fulfilling that unmet need, including those populations who have hesitancy with regards to the messenger RNA vaccines,\" he said after the vote. There are other advantages in terms of storage and supply chain challenges.In after-hours action, NVAX stock soared 22.86% to 58.41. Shares were halted during the regular session ahead of the vote.NVAX Stock: FDA Decision NextThe meeting is an important step ahead of potential authorization of the two-dose vaccine. Out of 22 panelists, 21 said the benefits of the Novavax shot outweigh its risks for adults. The FDA often follows the committee's recommendation.After that, the vaccine heads to the Centers for Disease Control and Prevention.Dr. Peter Marks, of the FDA, acknowledged the benefit of offering another vaccine option to help prevent severe cases of Covid. But it will be up to the CDC to determine where it lies in the lineup of preferred vaccines.Panelist Dr. Mark Sawyer notes the audience for the Novavax vaccine is largely \"vaccine-hesitant people,\" many of whom have likely already experienced natural Covid infections.In one of its key studies, 7% of participants had prior Covid infections before receiving Novavax's shot. Their responses were not calculated in the effectiveness analysis. However, in general, they experienced a boost in antibodies, Novavax Chief Medical Officer Filip Dubovsky said. They also didn't have any additional side effects compared to previously uninfected participants.Data Updates DesiredNovavax tested its Covid shot against an ancestral strain of the Covid-causing virus — just like its predecessors Pfizer, Moderna andJohnson & Johnson(JNJ). And it's beginning to look like vaccine-induced immunity lasts six months or less with new variants on the loose.\"It is disappointing that we don't have more updated information because we're looking at the (effectiveness) against strains that don't exist any longer,\" panelist Dr. Eric Rubin said. But \"if there's a population of patients who are going to take this and not existing vaccines, then I think it's pretty compelling.\"Still,NVAX stockremains under pressure. As of Monday's close, shares were below their50-dayand200-daymoving averages, according toMarketSmith.com. The stock also experienced a dive last week when the FDA posted briefing documents ahead of the advisory committee meeting.The documents suggested Novavax's shot could cause heart inflammation known as myocarditis and pericarditis.  The FDA noted there were six cases in recipients of the vaccine. In comparison, there was just one case in a placebo recipient.Young Males Are More SusceptibleOf the six cases, four occurred in males under the age of 30. The FDA said it couldn't rule out a causal relationship between Novavax's vaccine and the cases of myocarditis, causing NVAX stock to dive. But Novavax argued this demographic is at a heightened risk of myocarditis due to viral infection. In fact, myocarditis is a risk of Pfizer's and Moderna's vaccines in young men and boys.\"We have learned that we can expect to see natural background events of myocarditis in any sufficiently large database, and that young males are at higher risk,\" Novavax said in a written statement. \"Myocarditis is most often caused by nonspecific viral infections.\"The company said there's \"insufficient evidence to establish a causal relationship\" between its shot and episodes of myocarditis/pericarditis. Still,NVAX stock tumbled20% on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}